Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2168 studies found for:    "Lymphoma, Non-Hodgkin"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease;   Multiple Myeloma
Interventions: Drug: TXA127;   Drug: Placebo
2 Completed Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Conditions: Leukemia;   Lymphoma, Non-Hodgkin;   Hodgkin Disease;   Myelodysplastic Syndromes;   Multiple Myeloma
Interventions: Genetic: CD34-TK75 transduced donor lymphocytes;   Radiation: Sub Study - 18 FHBG PET/CT Scans
3 Active, not recruiting Randomized Double Cord Blood Transplant Study
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia, Myelocytic, Acute;   Leukemia, Myeloid, Chronic;   Lymphoma, Non-Hodgkin
Interventions: Procedure: Expanded allogeneic cord blood (CB);   Procedure: One Unmanipulated and One Expanded Cord Blood Unit;   Drug: Rituxan;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna
4 Completed Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-40;   Drug: rituximab;   Drug: gemcitabine
5 Terminated A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-40;   Drug: placebo;   Drug: rituximab;   Drug: etoposide;   Drug: carboplatin;   Drug: ifosfamide
6 Completed A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
7 Active, not recruiting A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: rituximab
8 Completed A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Giant Lymph Node Hyperplasia
Intervention: Drug: CNTO 328
9 Completed Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   HIV Infections
Intervention: Drug: Peripheral blood stem cells
10 Terminated
Has Results
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
Conditions: Leukemia;   Cancer;   Lymphoma;   Lymphoma, Hodgkin;   Lymphoma, Non-Hodgkin
Interventions: Drug: Ara C;   Drug: Mesna;   Drug: Cyclophosphamide;   Radiation: TBI-Total Body Irradiation
11 Completed Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Conditions: Neoplasms by Site;   Lymphoma, Non-hodgkin;   Hodgkin Disease;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic
Intervention: Drug: PCI-24781
12 Completed A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   HIV Infections
Intervention: Drug: Mitoguazone
13 Completed Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: recombinant human interleukin 21 and rituximab
14 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
15 Terminated Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Zevalin
16 Recruiting Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Procedure: Stem cell infusion;   Procedure: TLI;   Drug: Anti-thymocyte globulin;   Drug: Solumedrol;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
17 Recruiting ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Drug: cyclophosphamide
18 Completed Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-40
19 Active, not recruiting
Has Results
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
20 Completed Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Conditions: Carcinomas;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Neoplasms
Interventions: Drug: brentuximab vedotin;   Drug: rifampin;   Drug: midazolam;   Drug: ketoconazole

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years